title: [Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].
abstract: Anthracyclines including doxorubicin, epirubicin, daunorubicin, aclarubicin are extensively used as chemotherapeutic agents for treatment of hematological and other malignancies. In cancer therapy anthracyclines are often used in combinations with other chemotherapeutic drugs and agents for molecularly targeted therapy. Anthracyclines are effective and powerful antineoplastic drugs with wide spectrum of application but active use of preparations of this group is limited because of such side effects as cardiotoxicity, myelotoxicity, thromboembolism, alopecia, etc. Cardiotoxicity is the most severe side effect of anthracycline administration. Clinical studies have shown that it is progressive and irreversible. Therefore, early detection and prevention of anthracycline cardiotoxicity has become an important trend in cardiology.
authors.affiliation: A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.|City Clinical Hospital of brothers Bakhrushins of Moscow Health Departmen, Russia.
authors.forename: Y A
authors.initials: YA
authors.lastname: Vasyuk
authors.affiliation: A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.|City Clinical Hospital of brothers Bakhrushins of Moscow Health Departmen, Russia.
authors.forename: E L
authors.initials: EL
authors.lastname: Shkolnik
authors.affiliation: A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.|City Clinical Hospital of brothers Bakhrushins of Moscow Health Departmen, Russia.
authors.forename: V V
authors.initials: VV
authors.lastname: Nesterov
authors.affiliation: A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.|City Clinical Hospital of brothers Bakhrushins of Moscow Health Departmen, Russia.
authors.forename: L D
authors.initials: LD
authors.lastname: Shkolnik
authors.affiliation: A.I. Evdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia.|City Clinical Hospital of brothers Bakhrushins of Moscow Health Departmen, Russia.
authors.forename: G V
authors.initials: GV
authors.lastname: Varlan
mesh_terms: D015250:Aclarubicin / Q000009:adverse effects / Q000031:analogs & derivatives; D018943:Anthracyclines / Q000009:adverse effects*; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D066126:Cardiotoxicity; D004317:Doxorubicin / Q000009:adverse effects; D015251:Epirubicin / Q000009:adverse effects; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; C011157:aclacinomycins; D015251:Epirubicin; D015250:Aclarubicin; D004317:Doxorubicin
keywords: antratsikliniovaya cardiotoxicity; chemotherapy; prevention; treatment; trimetazidine MB